Stereotactic Radiosurgery for Oligometastatic Cancers in Indian patients
Not Applicable
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2022/01/039657
- Lead Sponsor
- Amrita Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age 18 or older
2. Willing to provide informed consent
3. Histologically proven malignancy with oligometastatic disease detected on imaging
4. Maximum 3 metastases in one organ and total of 5 metastases and below
5. Life expectancy of more than 6 months
Exclusion Criteria
•Pleural effusion
•Dominant brain metastasis requiring surgical decompression
•Pregnant or lactating women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the Overall Survival in patients treated for oligometastatic diseaseTimepoint: 5 years
- Secondary Outcome Measures
Name Time Method 1.To assess the local control at the site treated with Stereotactic Radiosurgery and stereotactic Body Radiotherapy <br/ ><br> <br/ ><br>2.To assess the progression free survivalTimepoint: 5 years